Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is poised for significant revenue growth with the launch of Xphozah and potential FDA approval for Ibsrela in the second half of 2027. The company's innovative platform and promising drug candidates address unmet medical needs and have the potential for high peak sales, making it an attractive investment opportunity. With the support of ArdelyxAssist, the company is well-positioned to successfully market and sell its drugs, further driving revenue and shareholder value.

Bears say

Ardelyx is facing potential challenges with the market expansion of Ibsrela and Xphozah into other conditions such as CIC, as their underlying diseases may be less severe in comparison to those currently treated by the drugs. The expected increase in R&D and SG&A expenses may also have a negative impact on their financials and valuation. In addition, there is a risk of regulatory hurdles and changes in reimbursement pricing that could limit the company's traction in the market.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.